Mobile App

Google Play Apple Store
Talking Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Improving Outcomes of Frontline Treatment and Mitigating Relapse
AMA Activity
Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.

This certified AMA activity will highlight the practice-changing updates in the frontline treatment of Ph+ ALL and provide guidance on effective implementation of new evidence through expert-guided discussions and interactive case scenarios.
Review each video to claim AMA credit/contact hour(s) after completion of the brief Post-Test/Evaluations.

Katarzyna Jamieson, MD Katarzyna Jamieson, MD
Associate Professor
University of North Carolina, Chapel Hill Department of Medicine
Farhad Ravandi, MD Farhad Ravandi, MD
Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Richard Stone, MD Richard Stone, MD
Chief of Staff
Director of Translational Research
Adult Leukemia Program
Dana Farber Cancer Institute

Supported by an independent educational grant from Amgen

Launch Date: August 23, 2022
Release Date: August 23, 2022
Expiration Date: July 31, 2023

July 31, 2023
Mini Module